Submission Formats, Documents and Samples for Belarus Registration
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Submission for registration in Belarus is not a single packaged event; electronic documents, paper files and samples advance in three parallel lines, and the point at which samples arrive directly decides whether the tests can start. Desynchronization of the three lines is a common cause of losing time against the total limit of 90 calendar days.
The practical meaning of the three-line structure is that submission readiness is a state of the whole project, not of the documents alone. A dossier that is complete but unsupported by samples is as far from the start of review as a dossier that has not been written. Planning should measure readiness across all three lines, and report progress in those terms to the decision-makers who set the launch dates.
2. Legal basis
| Regulation | Number or identifier | Date of publication or entry into force | Key provisions |
|---|---|---|---|
| On Preliminary Technical Work Prior to State Registration | Ministry of Health No. 55 (amended by No. 120 of 2023-08-23) | 2015-04-23 | Submission requirements for documents and samples |
| On State Registration (Re-registration) of Medical Devices | Council of Ministers No. 211 (6-1/55925) | Effective 2026-05-01 | Total time limit of 90 calendar days for preliminary technical work |
| List of institutional services | — | Current webpage | Acceptance and organization by the expert body |
| Amendment | Council of Ministers No. 378 (6-2/56159) | Effective 2026-07-30 | Amends No. 211 |
3. Expert insights
Insight one: samples are the critical path, not a supporting task. Both the technical tests and the biological tests start only when the samples are in place. If the samples are arranged only after the documents are finalized, testing becomes the bottleneck of the entire preliminary technical work. GRZAN recommends scheduling sample preparation and document preparation as parallel tasks rather than consecutive ones, with a shared milestone so that neither line races ahead of the other.
Insight two: the samples themselves are an object of review. The specifications, batch numbers, packaging and labeling of the samples should match the documents submitted. If review finds that the samples do not correspond to the description in the documents, new samples will be requested, which consumes the total time limit directly. A one-day mismatch found before shipping costs nothing; the same mismatch found during review can cost weeks.
Insight three: the value of electronic documents lies in searchability. The way the documents are organized, the naming rules and their retrievability directly affect review efficiency. Structured, searchable electronic files are better received than bare scans and pass the formal completeness check more easily, because the reviewer can locate each annex without opening every file in turn.
Insight four: statements about electronic submission should be made with care. Some Chinese-language accounts describe the reform under No. 211 as introducing electronic submission, but the official communications in Russian and English contain no corresponding statement of a new legal requirement. GRZAN treats this as pending verification and does not present it as a legal requirement in formal documents.
Insight five: the three lines converge at the moment of acceptance, and that moment belongs on the plan. Working backwards from the intended submission date, the sample lead time, the test durations and the document finalization schedule should all be placed on one calendar, with the samples marked as the earliest milestone, because every downstream activity waits for them. Where the three lines are owned by different teams, a weekly synchronization on this single calendar is the minimum mechanism that keeps the 90-day clock from being wasted before it even starts. The same calendar makes the trade-offs visible: if the tests must start earlier, the samples must ship earlier, and the document freeze must move with them.
4. Practical recommendations
- Prepare samples in parallel with documents. Put sample preparation at the front of the project master plan, not after the documents are finalized.
- Run a sample-to-document consistency check before shipping. Compare specifications, batch numbers, packaging and labeling item by item.
- Organize electronic documents to a searchable standard. Apply a unified naming scheme and avoid submitting pure scans.
- Make no external commitment on electronic submission. Follow the actual acceptance practice of the implementing organization, and keep unverified content out of client proposals.
5. Verification checklist
- □ Sample preparation has been scheduled in parallel with document preparation
- □ The consistency check between samples and documents is complete before shipping
- □ Electronic documents are organized under a unified naming scheme and are searchable
- □ External documents contain no commitments on pending verification matters such as electronic submission
- □ The progress of all three lines is tracked in the same project master plan
Regulatory information verified as of October 30, 2026.
In the Eurasian Economic Union market, the core capabilities of GRZAN concentrate on three points. First, distinguishing between the two channels of Union-wide registration and national registration in each member state, including their applicable conditions and remaining time windows. The national registration procedure of Belarus has been fully restructured by Council of Ministers Resolution No. 211 of April 28, 2026 (state register number 6-1/55925, effective May 1, 2026), which compressed the total time limit for preliminary technical work to 90 calendar days, applied a closed list that the implementing organization is prohibited from expanding, while applications under the national procedure face the key deadline of December 31, 2027, so pathway selection must be decided in sync with the time window. Second, local authorized representative services, acting as the legal representative of the manufacturer in Belarus, handling registration submission, responses to technical queries, changes to the registration dossier, and post-market reporting obligations; GRZAN has updated its coordination mechanisms after Council of Ministers Resolution No. 378 of July 27, 2026 (effective July 30, 2026) transferred adverse event functions to the state institution Gosfarmnadzor. Third, quality system and testing support, assisting in establishing a quality management system compliant with ISO 13485 and organizing the technical documentation according to the target pathway: for the national pathway, the annex to Ministry of Health Resolution No. 55; for the Union pathway, Decision No. 46 of the Council of the Eurasian Economic Commission.
Business inquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us